BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37665776)

  • 1. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.
    Karschnia P; Dietrich J; Bruno F; Dono A; Juenger ST; Teske N; Young JS; Sciortino T; Häni L; van den Bent M; Weller M; Vogelbaum MA; Morshed RA; Haddad AF; Molinaro AM; Tandon N; Beck J; Schnell O; Bello L; Hervey-Jumper S; Thon N; Grau SJ; Esquenazi Y; Rudà R; Chang SM; Berger MS; Cahill DP; Tonn JC
    Neuro Oncol; 2024 Jan; 26(1):166-177. PubMed ID: 37665776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
    Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
    Neuro Oncol; 2023 Sep; 25(9):1672-1685. PubMed ID: 37253096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.
    Karschnia P; Young JS; Dono A; Häni L; Sciortino T; Bruno F; Juenger ST; Teske N; Morshed RA; Haddad AF; Zhang Y; Stoecklein S; Weller M; Vogelbaum MA; Beck J; Tandon N; Hervey-Jumper S; Molinaro AM; Rudà R; Bello L; Schnell O; Esquenazi Y; Ruge MI; Grau SJ; Berger MS; Chang SM; van den Bent M; Tonn JC
    Neuro Oncol; 2023 May; 25(5):940-954. PubMed ID: 35961053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification.
    Tropeano MP; Raspagliesi L; Bono BC; Baram A; Rossini Z; Franzini A; Navarria P; Clerici E; Bellu L; Simonelli M; Scorsetti M; Riva M; Politi LS; Pessina F
    Acta Neurochir (Wien); 2024 Apr; 166(1):196. PubMed ID: 38676720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes.
    Mampre D; Ehresman J; Pinilla-Monsalve G; Osorio MAG; Olivi A; Quinones-Hinojosa A; Chaichana KL
    Br J Neurosurg; 2018 Oct; 32(5):528-535. PubMed ID: 30073866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of radiological findings on early postoperative MRI for 187 consecutive glioblastoma patients receiving standard therapy.
    Rykkje AM; Carlsen JF; Larsen VA; Skjøth-Rasmussen J; Christensen IJ; Nielsen MB; Poulsen HS; Urup TH; Hansen AE
    Sci Rep; 2024 May; 14(1):10985. PubMed ID: 38744979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
    Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
    J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma.
    Incekara F; Smits M; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Kros JM; Vincent AJPE; van den Bent M
    Front Oncol; 2020; 10():1087. PubMed ID: 32766140
    [No Abstract]   [Full Text] [Related]  

  • 14. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
    Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Peritumoral Brain Parenchyma Using Contrast-Enhanced 3D Fast Imaging Employing Steady-State Acquisition at 3T for Differentiating Metastatic Brain Tumors and Glioblastomas.
    Yamamoto J; Kakeda S; Shimajiri S; Nakano Y; Saito T; Ide S; Moriya J; Korogi Y; Nishizawa S
    World Neurosurg; 2018 Dec; 120():e719-e729. PubMed ID: 30165229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance.
    Neira JA; Ung TH; Sims JS; Malone HR; Chow DS; Samanamud JL; Zanazzi GJ; Guo X; Bowden SG; Zhao B; Sheth SA; McKhann GM; Sisti MB; Canoll P; D'Amico RS; Bruce JN
    J Neurosurg; 2017 Jul; 127(1):111-122. PubMed ID: 27715437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
    Bjorland LS; Mahesparan R; Fluge Ø; Gilje B; Dæhli Kurz K; Farbu E
    Neurooncol Adv; 2023; 5(1):vdad126. PubMed ID: 37868696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.
    Kiesel B; Mischkulnig M; Woehrer A; Martinez-Moreno M; Millesi M; Mallouhi A; Czech T; Preusser M; Hainfellner JA; Wolfsberger S; Knosp E; Widhalm G
    J Neurosurg; 2018 Aug; 129(2):341-353. PubMed ID: 29076783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial.
    Roder C; Stummer W; Coburger J; Scherer M; Haas P; von der Brelie C; Kamp MA; Löhr M; Hamisch CA; Skardelly M; Scholz T; Schipmann S; Rathert J; Brand CM; Pala A; Ernemann U; Stockhammer F; Gerlach R; Kremer P; Goldbrunner R; Ernestus RI; Sabel M; Rohde V; Tabatabai G; Martus P; Bisdas S; Ganslandt O; Unterberg A; Wirtz CR; Tatagiba M
    J Clin Oncol; 2023 Dec; 41(36):5512-5523. PubMed ID: 37335962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?
    Xing Y; Wang X
    World Neurosurg; 2018 Aug; 116():e444-e451. PubMed ID: 29753893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.